This article is part of the supplement: The role of IFN alpha in autoimmune disease
Type 1 interferons and myositis
Department of Neurology, Division of Neuromuscular Disease, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
Arthritis Research & Therapy 2010, 12(Suppl 1):S4 doi:10.1186/ar2885Published: 14 April 2010
Recent studies suggest a mechanistic role for molecules induced by type 1 interferons in the pathogenesis of some forms of myositis. For dermatomyositis, evidence that these molecules injure myofibers seems especially strong. In the group of disorders known as polymyositis, the study of blood samples suggests a potential role. It is unknown what drives the sustained presence of type 1 interferon-inducible molecules in these diseases, as the type 1 interferons themselves have not been specifically detected along with their downstream biomarkers. Therapeutic development for blockade of IFNα is in progress aided by the identification of blood genomic biomarkers.